Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 129 Melanoma 90 Squamous Cell Carcinoma of Head and Neck 88 Breast Neoplasms 70 Triple Negative Breast Neoplasms 64 Parkinson Disease 4, Autosomal Dominant Lewy Body 45 Head and Neck Neoplasms 45 Lung Neoplasms 38 Ovarian Neoplasms 37 Neoplasms 37 Neoplasm Metastasis 37 Colorectal Neoplasms 37 Stomach Neoplasms 36 Carcinoma, Renal Cell 34 Carcinoma, Transitional Cell 31 Pancreatic Neoplasms 29 Urinary Bladder Neoplasms 28 Carcinoma, Hepatocellular 27 Recurrence 21 Hodgkin Disease 21 Uterine Cervical Neoplasms 20 Endometrial Neoplasms 20 Prostatic Neoplasms 18 Esophageal Neoplasms 18 Sarcoma 17 Glioblastoma 17 Brain Neoplasms 16 Fallopian Tube Neoplasms 15 Esophageal Squamous Cell Carcinoma 15 Carcinoma, Squamous Cell 14

Interventions

Tamoxifen 2 Paclitaxel 2 pyrotinib 1 pembrolizumab 1 palbociclib 1 iniparib 1 darolutamide 1 Thioctic Acid 1 Pentoxifylline 1 Metformin 1 Letrozole 1 Doxorubicin 1 Cyclophosphamide 1 Capecitabine 1 Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Female × pembrolizumab × Clear all

NCT03879174 2019-03-18

Pembro

Mediclinic Middle East

Phase 2 Unknown

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡